Toth Financial Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $101K | Sell |
4,200
-788
| -16% | -$20.6K | 0.01% | 296 |
|
|
2026
Q1 | $140K | Buy |
4,988
+3,579
| +254% | +$95.3K | 0.02% | 245 |
|
|
2025
Q4 | $35.1K | Buy |
1,409
+9
| +0.6% | +$227 | ﹤0.01% | 405 |
|
|
2025
Q3 | $35.7K | Sell |
1,400
-793
| -36% | -$19.6K | ﹤0.01% | 400 |
|
|
2025
Q2 | $53.2K | Sell |
2,193
-796
| -27% | -$18.6K | 0.01% | 297 |
|
|
2025
Q1 | $75.7K | Buy |
2,989
+291
| +11% | +$7.62K | 0.01% | 258 |
|
|
2024
Q4 | $71.6K | Buy |
2,698
+8
| +0.3% | +$217 | 0.01% | 263 |
|
|
2024
Q3 | $77.9K | Sell |
2,690
-1,028
| -28% | -$30K | 0.01% | 252 |
|
|
2024
Q2 | $104K | Buy |
3,718
+7
| +0.2% | +$193 | 0.01% | 235 |
|
|
2024
Q1 | $103K | Sell |
3,711
-158
| -4% | -$4.38K | 0.01% | 236 |
|
|
2023
Q4 | $111K | Buy |
3,869
+5
| +0.1% | +$151 | 0.02% | 232 |
|
|
2023
Q3 | $128K | Sell |
3,864
-975
| -20% | -$34.5K | 0.02% | 211 |
|
|
2023
Q2 | $177K | Buy |
4,839
+709
| +17% | +$27.6K | 0.03% | 203 |
|
|
2023
Q1 | $168K | Sell |
4,130
-318
| -7% | -$13.7K | 0.03% | 197 |
|
|
2022
Q4 | $228K | Sell |
4,448
-158
| -3% | -$7.58K | 0.04% | 181 |
|
|
2022
Q3 | $202K | Buy |
4,606
+173
| +4% | +$8.41K | 0.04% | 168 |
|
|
2022
Q2 | $232K | Sell |
4,433
-31
| -0.7% | -$1.58K | 0.04% | 169 |
|
|
2022
Q1 | $231K | Buy |
4,464
+77
| +2% | +$4K | 0.03% | 183 |
|
|
2021
Q4 | $259K | Buy |
4,387
+7
| +0.2% | +$347 | 0.04% | 190 |
|
|
2021
Q3 | $188K | Buy |
4,380
+8
| +0.2% | +$354 | 0.03% | 199 |
|
|
2021
Q2 | $171K | Sell |
4,372
-32
| -0.7% | -$1.24K | 0.03% | 184 |
|
|
2021
Q1 | $160K | Buy |
4,404
+10
| +0.2% | +$355 | 0.03% | 206 |
|
|
2020
Q4 | $162K | Sell |
4,394
-188
| -4% | -$6.9K | 0.03% | 191 |
|
|
2020
Q3 | $160K | Buy |
4,582
+741
| +19% | +$26K | 0.03% | 190 |
|
|
2020
Q2 | $119K | Buy |
3,841
+858
| +29% | +$29.1K | 0.03% | 184 |
|
|
2020
Q1 | $92K | Sell |
2,983
-99
| -3% | -$3.37K | 0.03% | 144 |
|
|
2019
Q4 | $115K | Buy |
3,082
+9
| +0.3% | +$321 | 0.02% | 174 |
|
|
2019
Q3 | $105K | Buy |
3,073
+9
| +0.3% | +$327 | 0.02% | 188 |
|
|
2019
Q2 | $126K | Buy |
3,064
+7
| +0.2% | +$278 | 0.03% | 176 |
|
|
2019
Q1 | $123K | Buy |
3,057
+112
| +4% | +$4.49K | 0.03% | 165 |
|
|
2018
Q4 | $122K | Buy |
2,945
+6
| +0.2% | +$249 | 0.03% | 142 |
|
|
2018
Q3 | $123K | Buy |
2,939
+7
| +0.2% | +$269 | 0.03% | 166 |
|
|
2018
Q2 | $101K | Buy |
2,932
+7
| +0.2% | +$239 | 0.02% | 172 |
|
|
2018
Q1 | $98K | Buy |
2,925
+8
| +0.3% | +$275 | 0.02% | 171 |
|
|
2017
Q4 | $100K | Buy |
+2,917
| New | +$99.5K | 0.02% | 168 |
|
Other funds holding PFE
Toth Financial Advisory's PFE Position: Q2 2026 in Review
Toth Financial Advisory reduced its Pfizer (PFE) stake by 16% in Q2 2026, selling an estimated $20.6K and leaving 4,200 shares worth $101K. The position accounts for 0.01% of the portfolio, ranked #296.
Toth Financial Advisory first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $259K in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Toth Financial Advisory held 4,200 shares of Pfizer worth $101K as of Q2 2026.
- Toth Financial Advisory sold 788 Pfizer shares in Q2 2026, an estimated $20.6K.
- Pfizer made up 0.01% of Toth Financial Advisory's portfolio in Q2 2026, its #296 holding.
- Toth Financial Advisory first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Toth Financial Advisory's Pfizer position peaked at $259K in Q4 2021.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.